{
    "name": "influenza virus vaccine quadrivalent",
    "comment": "Rx",
    "other_names": [
        "Fluarix Quadrivalent",
        "Fluzone Quadrivalent",
        "FluLaval Quadrivalent",
        "Afluria Quadrivalent",
        "Fluzone High-Dose Quadrivalent",
        "Fluzone Intradermal Quadrivalent (DSC)"
    ],
    "classes": [
        "Vaccines",
        "Inactivated",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/fluarix-quadrivalent-fluzone-quadrivalent-influenza-virus-vaccine-quadrivalent-999829",
    "pregnancy": {
        "common": [
            "There are insufficient data on influenza vaccine in pregnant women to inform vaccine-associated risk"
        ],
        "specific": [
            {
                "type": "Pregnancy exposure registry",
                "description": [
                    "Monitors pregnancy outcomes in women exposed to influenza vaccine during pregnancy",
                    "Healthcare providers are encouraged to register women by calling the following: H5",
                    "FluLaval Quadrivalent, Fluarix Quadrivalent: 1-888-452-9622",
                    "Afluria Quadrivalent: 1-855-358-8966 or sending an email to Seqirus at ",
                    "Fluzone Intradermal Quadrivalent or Fluzone Quadrivalent: 1-800-822-2463"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "No adverse effects observed on preweaning or vaccine-related fetal malformations when administered to female rabbits before pregnancy or during pregnancy"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Pregnant women are at increased risk of complications associated with influenza infection compared with nonpregnant women",
                    "The CDC recommends pregnant women be immunized with influenza vaccine by injection and not the live-attenuated influenza vaccine (LAIV; intranasal influenza vaccine)",
                    "Vaccination has been shown to reduce the risk of flu-associated acute respiratory infection in pregnant women by up to 50%; immunization also confers some immunity to infants for the first several months after their birth, when they are too young to be vaccinated"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Severe hypersensitivity (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous administration of any influenza vaccine"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of vaccine",
                "Use split or purified surface antigen in children",
                "Defer vaccine with febrile illnesses until illness is resolved; may administer vaccine with minor illnesses without fever (eg, upper respiratory tract infections)",
                "Expected immune response may not be obtained in immunocompromised individuals, including those receiving immunosuppressive therapy",
                "Guillain-Barré syndrome has been reported within 6 weeks of receipt of influenza vaccines",
                "Tip of syringe may contain natural rubber latex",
                "Syncope reported with injectable vaccines",
                "IM injections may cause hematoma in individuals with bleeding disorders (eg, hemophilia, anticoagulant therapy)",
                "Before administration, review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions",
                "Vaccination may not protect all susceptible individuals"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Do not mix with any other vaccine in the same syringe or vial",
                        "There are insufficient data to assess the coadministration of influenza vaccine with other vaccines",
                        "When concomitant administration of other vaccines is required, administer at different injection sites"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3 mo. after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adalimumab",
            "description": {
                "common": "adalimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alefacept",
            "description": {
                "common": "alefacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "anakinra",
            "description": {
                "common": "anakinra decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "antithymocyte globulin equine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "antithymocyte globulin rabbit decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azathioprine",
            "description": {
                "common": "azathioprine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "basiliximab",
            "description": {
                "common": "basiliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "budesonide",
            "description": {
                "common": "budesonide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "canakinumab",
            "description": {
                "common": "canakinumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cortisone",
            "description": {
                "common": "cortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deflazacort",
            "description": {
                "common": "deflazacort decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, influenza virus vaccine quadrivalent.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: The safety and effectiveness of vaccination during or following elivaldogene autotemcel treatment have not been studied. Vaccination is not recommended during the 6 weeks preceding myeloablative conditioning, and until hematological recovery following elivaldogene autotemcel treatment. Where feasible, administer childhood vaccinations before myeloablative conditioning. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etanercept",
            "description": {
                "common": "etanercept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "everolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "fludrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glatiramer",
            "description": {
                "common": "glatiramer decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "golimumab",
            "description": {
                "common": "golimumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "hydrocortisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infliximab",
            "description": {
                "common": "infliximab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leflunomide",
            "description": {
                "common": "leflunomide decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "methylprednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "muromonab CD3 decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "mycophenolate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "ocrelizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Vaccination with live-attenuated or live vaccines is not recommended during ocrelizumab treatment and until B-cell repletion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Administer all immunizations according to immunization guidelines at least 2 weeks before initiating ofatumumab SC for inactivated vaccines, and whenever possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisolone",
            "description": {
                "common": "prednisolone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prednisone",
            "description": {
                "common": "prednisone decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilonacept",
            "description": {
                "common": "rilonacept decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Prior to initiating secukinumab, complete all age appropriate immunizations; non-live vaccinations received during treatment with secukinumab may not elicit an immune response sufficient to prevent disease."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Pause vaccinations beginning 1 week before initiating siponimod and for 4 weeks after stopping treatment. Coadministration with live attenuated vaccines may increase infection risk."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sirolimus",
            "description": {
                "common": "sirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "tacrolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "temsirolimus decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teplizumab",
            "description": {
                "common": "teplizumab decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Avoid or Use Alternate Drug. \nComment: Administer all age-appropriate vaccinations before starting teplizumab. Inactivated or mRNA vaccines are not recommended within 2 weeks before teplizumab treatment, during treatment, or 6 weeks after completion of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "tocilizumab decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "triamcinolone acetonide injectable suspension decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Contraindicated. Corticosteroids also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "certolizumab pegol decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. If possible, complete all age-appropriate vaccinations at least 2 weeks before initiating immunosuppressant therapy. Patients vaccinated <14 days before starting immunosuppressive therapy or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued if immune competence has been restored. Longer waiting periods may be required for drugs that maintain their immunosuppressive effects for more than 3 months after discontinuation (eg, ocrelizumab). ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "dengue vaccine, influenza virus vaccine quadrivalent. unspecified interaction mechanism. Use Caution/Monitor. Data are not available to establish safety and immunogenicity of coadministration of dengue vaccine with recommended adolescent vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "ibrutinib decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "melphalan decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "mercaptopurine decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressants also increase risk of infection with concomitant live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "methotrexate decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "onasemnogene abeparvovec",
            "description": {
                "common": "onasemnogene abeparvovec decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Adjust vaccinations to accommodate concomitant corticosteroid administration prior to and following onasemnogene abeparvovec infusion. When initiating systemic corticosteriod therapy, wait 2 weeks after an inactivated vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oseltamivir",
            "description": {
                "common": "oseltamivir decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Use Caution/Monitor. Avoid administration of live attenuated influenza vaccine intranasal within 2 weeks before or 48 hours after administration of oseltamivir, unless medically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaliplatin",
            "description": {
                "common": "oxaliplatin decreases effects of influenza virus vaccine quadrivalent by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Use Caution/Monitor. If possible, complete all age-appropriate vaccinations at least 4 weeks before initiating ponesimod."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Coadministration with immunosuppressant therapy reduced efficacy of the vaccine may occur. If possible, complete all age-appropriate vaccinations at least 2 weeks prior to initiation of immunosuppressant therapy. Patients vaccinated <14 days before initiation or during immunosuppressive therapy should be revaccinated at least 3 months after therapy is discontinued. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab",
            "description": {
                "common": "rituximab, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "rituximab-hyaluronidase, influenza virus vaccine quadrivalent. immunosuppressive effects; risk of infection. Use Caution/Monitor. When used for rheumatoid arthritis, follow current immunization guidelines and administer non-live vaccines at least 4 weeks prior to a course of rituximab."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "satralizumab",
            "description": {
                "common": "satralizumab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines. At least 2 weeks before initiating for non-live vaccines. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tralokinumab",
            "description": {
                "common": "tralokinumab will decrease the level or effect of influenza virus vaccine quadrivalent by  immunosuppressive effects; risk of infection. Use Caution/Monitor. Limited data are available regarding coadministration with non-live vaccines."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Administer all immunizations according to immunization guidelines at least 4 weeks before initiating ublituximab for live or live-attenuated vaccines and, whenever possible, at least 2 weeks before initiating for non-live vaccines. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. Do not administer live or live-attenuated vaccines to infants of mothers exposed to ublituximab during pregnancy, before confirming recovery of B-cell counts as measured by CD19+ B cells."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Inactivated vaccines noted to be safe for administration may not be sufficiently immunogenic during treatment."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amantadine",
            "description": {
                "common": "amantadine decreases effects of influenza virus vaccine quadrivalent by Other (see comment). Minor/Significance Unknown. \nComment: Because of its antiviral properties, amantadine may interfere with the efficacy of live attenuated influenza vaccines (LAIV). Coadministration of LAIV and amantadine is not recommended. Inactivated influenza vaccines may be used, as appropriate."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "influenza virus vaccine quadrivalent, ethotoin. Mechanism: unknown. Minor/Significance Unknown. Vaccine administration may incr or decr phenytoin levels."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "influenza virus vaccine quadrivalent, fosphenytoin. Mechanism: unknown. Minor/Significance Unknown. Vaccine administration may incr or decr phenytoin levels."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod decreases effects of influenza virus vaccine quadrivalent by immunosuppressive effects; risk of infection. Minor/Significance Unknown. No clinical data are available on the efficacy and safety of vaccinations in patients taking ozanimod. Vaccinations may be less effective if coadministered with ozanimod."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "influenza virus vaccine quadrivalent, phenytoin. Mechanism: unknown. Minor/Significance Unknown. Vaccine administration may incr or decr phenytoin levels."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": "61-68"
        },
        {
            "name": "Myalgia",
            "percent": "8-40"
        },
        {
            "name": "Headache",
            "percent": "10-27"
        },
        {
            "name": "Redness",
            "percent": "17-24"
        },
        {
            "name": "Malaise",
            "percent": "8-24"
        },
        {
            "name": "Irritability",
            "percent": "16-18"
        },
        {
            "name": "Induration",
            "percent": "15-17"
        },
        {
            "name": "Swelling",
            "percent": "13-17"
        },
        {
            "name": "Any fever",
            "percent": "5-16"
        },
        {
            "name": "Nausea",
            "percent": "3-12"
        },
        {
            "name": "vomiting",
            "percent": "43.7"
        },
        {
            "name": "Pain",
            "percent": "23"
        },
        {
            "name": "Redness",
            "percent": "19.7"
        },
        {
            "name": "Fatigue",
            "percent": "18.5"
        },
        {
            "name": "Swelling",
            "percent": "17.5"
        },
        {
            "name": "Muscle aches",
            "percent": "17.2"
        },
        {
            "name": "Drowsiness",
            "percent": "16.8"
        },
        {
            "name": "Irritability",
            "percent": "16.3"
        },
        {
            "name": "Headache",
            "percent": "15.5"
        },
        {
            "name": "Loss of appetite",
            "percent": "11.9-13.4"
        },
        {
            "name": "Injection site erythema",
            "percent": "8.7-11.6"
        },
        {
            "name": "Injection site induration",
            "percent": "59.5"
        },
        {
            "name": "Pain",
            "percent": "26.3"
        },
        {
            "name": "Muscle aches",
            "percent": "21.5"
        },
        {
            "name": "Headaches",
            "percent": "21.5"
        },
        {
            "name": "Fatigue",
            "percent": "14.8"
        },
        {
            "name": "Arthralgia",
            "percent": "41.3"
        },
        {
            "name": "Injection site pain",
            "percent": "22.7"
        },
        {
            "name": "Myalgia",
            "percent": "14.4"
        },
        {
            "name": "Headache",
            "percent": "13.2"
        },
        {
            "name": "Malaise",
            "percent": "2-8"
        },
        {
            "name": "Diarrhea",
            "percent": "4-5"
        },
        {
            "name": "Loss of appetite",
            "percent": "9.8"
        },
        {
            "name": "Arthralgia",
            "percent": "9.8"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "8.9"
        },
        {
            "name": "Fever",
            "percent": "6.4"
        },
        {
            "name": "Shivering",
            "percent": "6"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Pain",
            "percent": "1.6"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "1.5"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "1.3"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fever",
            "percent": "1.1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Redness",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Drowsiness",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "1"
        },
        {
            "name": "Grade",
            "percent": "9.3"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "8.8"
        },
        {
            "name": "Shivering",
            "percent": "3"
        },
        {
            "name": "Pain",
            "percent": "1.7"
        },
        {
            "name": "Grade",
            "percent": "1.3"
        },
        {
            "name": "Fever",
            "percent": "3"
        },
        {
            "name": "Swelling",
            "percent": "0.8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Irritability",
            "percent": "0.7"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Muscle aches",
            "percent": "0.7"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Shivering",
            "percent": "0.5"
        },
        {
            "name": "Grade",
            "percent": "0.3"
        },
        {
            "name": "Loss of appetite",
            "percent": "0.3"
        },
        {
            "name": "Fever",
            "percent": "0.3-0.9"
        },
        {
            "name": "Headache",
            "percent": "0.6-0.8"
        },
        {
            "name": "Fatigue",
            "percent": "0.3-0.8"
        },
        {
            "name": "Myalgia",
            "percent": "0.5-0.6"
        },
        {
            "name": "Diarrhea",
            "percent": "0.3-0.5"
        },
        {
            "name": "Arthralgia",
            "percent": "0.5"
        },
        {
            "name": "Injection site pain",
            "percent": "0.2-0.3"
        },
        {
            "name": "Chills",
            "percent": "0.2-0.3"
        },
        {
            "name": "Nausea",
            "percent": "0.2-0.3"
        },
        {
            "name": "Loss of appetite",
            "percent": "0.2"
        },
        {
            "name": "Vomiting",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "0.9"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Muscle aches",
            "percent": "0.8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "0.8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Arthralgia",
            "percent": "0.8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Gastrointestinal symptoms",
            "percent": "0.8"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Shivering",
            "percent": "0.6"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fever",
            "percent": "0.4"
        },
        {
            "name": "Grade",
            "percent": null
        },
        {
            "name": "Blood and lymphatic disorders",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Allergic or immediate hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "including anaphylactic shock and serum sickness",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Neuralgia",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "convulsions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "febrile seizures",
            "percent": null
        },
        {
            "name": "encephalomyelitis",
            "percent": null
        },
        {
            "name": "encephalopathy",
            "percent": null
        },
        {
            "name": "neuritis or neuropathy",
            "percent": null
        },
        {
            "name": "transverse myelitis",
            "percent": null
        },
        {
            "name": "and Guillain",
            "percent": null
        },
        {
            "name": "Barré syndrome",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Vasculitis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "and rash",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Cellulitis",
            "percent": null
        },
        {
            "name": "large injection site swelling",
            "percent": null
        },
        {
            "name": "influenzalike illness",
            "percent": null
        },
        {
            "name": "Blood and lymphatic disorders",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Ear and labyrinth disorders",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Conjunctivitis",
            "percent": null
        },
        {
            "name": "eye irritation",
            "percent": null
        },
        {
            "name": "eye pain",
            "percent": null
        },
        {
            "name": "eye redness",
            "percent": null
        },
        {
            "name": "eye swelling",
            "percent": null
        },
        {
            "name": "eyelid swelling",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain or discomfort",
            "percent": null
        },
        {
            "name": "swelling of the mouth",
            "percent": null
        },
        {
            "name": "throat",
            "percent": null
        },
        {
            "name": "and",
            "percent": null
        },
        {
            "name": "or tongue",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "feeling hot",
            "percent": null
        },
        {
            "name": "injection site mass",
            "percent": null
        },
        {
            "name": "injection site reaction",
            "percent": null
        },
        {
            "name": "injection site warmth",
            "percent": null
        },
        {
            "name": "body aches",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Anaphylactic reaction",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "shock",
            "percent": null
        },
        {
            "name": "anaphylactoid reaction",
            "percent": null
        },
        {
            "name": "hypersensitivity",
            "percent": null
        },
        {
            "name": "serum sickness",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Injection site abscess",
            "percent": null
        },
        {
            "name": "injection site cellulitis",
            "percent": null
        },
        {
            "name": "pharyngitis",
            "percent": null
        },
        {
            "name": "rhinitis",
            "percent": null
        },
        {
            "name": "tonsillitis",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Convulsion",
            "percent": null
        },
        {
            "name": "encephalomyelitis",
            "percent": null
        },
        {
            "name": "facial palsy",
            "percent": null
        },
        {
            "name": "facial paresis",
            "percent": null
        },
        {
            "name": "Guillain",
            "percent": null
        },
        {
            "name": "Barré syndrome",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "myelitis",
            "percent": null
        },
        {
            "name": "neuritis",
            "percent": null
        },
        {
            "name": "neuropathy",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Asthma",
            "percent": null
        },
        {
            "name": "bronchospasm",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "respiratory distress",
            "percent": null
        },
        {
            "name": "stridor",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "erythema multiforme",
            "percent": null
        },
        {
            "name": "facial swelling",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "sweating",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Henoch",
            "percent": null
        },
        {
            "name": "Schönlein purpura",
            "percent": null
        },
        {
            "name": "vasculitis",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Allergic or immediate hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "anaphylactic shock",
            "percent": null
        },
        {
            "name": "Nervous systems disorders",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "presyncope",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Generalized skin reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "nonspecific rash",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Extensive swelling of injected limb",
            "percent": null
        },
        {
            "name": "Blood and lymphatic disorders",
            "percent": null
        },
        {
            "name": "Lymphadenopathy",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "photophobia",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Dysphagia",
            "percent": null
        },
        {
            "name": "vomiting",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "injection site inflammation",
            "percent": null
        },
        {
            "name": "asthenia",
            "percent": null
        },
        {
            "name": "injection site rash",
            "percent": null
        },
        {
            "name": "influenzalike symptoms",
            "percent": null
        },
        {
            "name": "abnormal gait",
            "percent": null
        },
        {
            "name": "injection site bruising",
            "percent": null
        },
        {
            "name": "injection site sterile abscess",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        },
        {
            "name": "including anaphylaxis",
            "percent": null
        },
        {
            "name": "angioedema",
            "percent": null
        },
        {
            "name": "Infections and infestations",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "laryngitis",
            "percent": null
        },
        {
            "name": "cellulitis",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective",
            "percent": null
        },
        {
            "name": "tissue disorders",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        },
        {
            "name": "arthritis",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "paresthesia",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "hypokinesia",
            "percent": null
        },
        {
            "name": "tremor",
            "percent": null
        },
        {
            "name": "somnolence",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "Guillain",
            "percent": null
        },
        {
            "name": "Barré syndrome",
            "percent": null
        },
        {
            "name": "convulsions",
            "percent": null
        },
        {
            "name": "seizures",
            "percent": null
        },
        {
            "name": "facial or cranial nerve paralysis",
            "percent": null
        },
        {
            "name": "encephalopathy",
            "percent": null
        },
        {
            "name": "limb paralysis",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic",
            "percent": null
        },
        {
            "name": "and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "dysphonia",
            "percent": null
        },
        {
            "name": "bronchospasm",
            "percent": null
        },
        {
            "name": "throat tightness",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "localized or generalized rash",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "sweating",
            "percent": null
        },
        {
            "name": "Vascular disorders",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "pallor",
            "percent": null
        }
    ]
}